1.
Mato AR, Sharman JP, Biondo JM, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i&gt; analyses from the phase III MURANO study. Haematologica 2020;107(1):134-142; https://doi.org/10.3324/haematol.2020.266486.